Holen Sie sich die Stockscreener-App
38.64
1.56%
-0.5589
Schlusskurs vom Vortag:
$39.20
Offen:
$39.53
24-Stunden-Volumen:
29,867
Relative Volume:
0.13
Marktkapitalisierung:
$999.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-184.46M
KGV:
-0.2707
EPS:
-142.7277
Netto-Cashflow:
$-24.11M
1W Leistung:
-1.36%
1M Leistung:
+58.21%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$38.11
$40.17
1-Wochen-Bereich:
$37.37
$42.14
52-Wochen-Spanne:
$17.50
$42.14
Faeth Therapeutics Inc Stock (FTH) Company Profile
Firmenname
Faeth Therapeutics Inc
Sektor
Branche
Telefon
(240) 243-8000
Adresse
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
38.69 | 1.01B | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Aktie (FTH) Neueste Nachrichten
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com India
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - BioSpace
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Australia
Faeth Therapeutics stock hits 52-week high at 40.89 USD - Investing.com
Bullish Faeth Therapeutics Insiders Rewarded As Their Investment Rises To US$1.94m - simplywall.st
Insiders of Faeth Therapeutics Getting Good Value On Their US$1.19m Investment - Moomoo
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Eastern Progress
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Yahoo Finance Singapore
Faeth Therapeutics (FTH) Grants Stock Options to New Hires Amid Unprofitable Growth Phase - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Capital expenditures of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know - Yahoo Finance
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - kalkine.ca
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz.co
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - BioSpace
Faeth Therapeutics names two senior vice presidents - Investing.com
Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues (FTH) - Seeking Alpha
Faeth Therapeutics (FTH) holder files to sell 130K shares under Rule 144 - Stock Titan
Form 144 | Faeth Therapeutics(FTH.US) 10% Stockholder Proposes to Sell 3.64 Million in Common Stocks - Moomoo
FTH Reiterated by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Business Wire
H.C. Wainwright Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Faeth Therapeutics Presents Pk/Pd Modeling That Informs Piktor Dose Selection in Ongoing Fth-Pik-201 Trial - marketscreener.com
Oppenheimer Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - moomoo.com
Faeth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FTH Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Faeth Therapeutics (FTH) Advances Cancer Research with Merger an - GuruFocus
Faeth Therapeutics, Inc. Q2 2026: Net loss $(16.0M), EPS $(2.84) — 10-Q Summary - TradingView
Faeth Therapeutics Posts $16.0 Million Q2 Net Loss - Quiver Quantitative
Faeth Therapeutics reports $16.0M Q2 net loss, $186.4M cash and marketable securities - TradingView
FTH: Strong cash position and clinical progress with PIKTOR, topline data expected by year-end 2026 - TradingView
Finanzdaten der Faeth Therapeutics Inc-Aktie (FTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Faeth Therapeutics Inc-Aktie (FTH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 30 '26 |
Buy |
24.25 |
7,803 |
189,240 |
41,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jul 01 '26 |
Buy |
23.50 |
5,000 |
117,492 |
46,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 29 '26 |
Buy |
23.34 |
831 |
19,396 |
33,885 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 24 '26 |
Buy |
26.13 |
9,391 |
245,360 |
26,804 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 26 '26 |
Buy |
24.95 |
6,250 |
155,908 |
33,054 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 23 '26 |
Buy |
24.36 |
9,230 |
224,806 |
17,413 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 22 '26 |
Buy |
22.13 |
8,183 |
181,115 |
8,183 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Option Exercise |
1.16 |
53,465 |
62,019 |
817,699 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Buy |
19.76 |
2,806 |
55,447 |
764,234 |
| Cambrian BioPharma Inc | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):